Clinical Trials Logo

Late-onset Pompe Disease clinical trials

View clinical trials related to Late-onset Pompe Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05431127 Recruiting - Clinical trials for Late-Onset Pompe Disease

High Dose Inspiratory Muscle Training in LOPD

Start date: July 19, 2022
Phase: N/A
Study type: Interventional

Study Objectives: 1) assess the safety and feasibility of high-dose inspiratory muscle training (IMT) delivered remotely in Late-onset Pompe Disease (LOPD) and 2) determine its effects on respiratory and patient-reported outcomes.

NCT ID: NCT03347253 Terminated - Clinical trials for Late-onset Pompe Disease

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Start date: December 8, 2017
Phase:
Study type: Observational

The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) subjects receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained may be used in the design and conduct of future studies in LOPD subjects.

NCT ID: NCT03045042 Not yet recruiting - Pompe Disease Clinical Trials

Search for Serum/Plasma Biomarkers in Pompe's Disease

BIOPOMPE
Start date: April 2017
Phase: N/A
Study type: Observational

This study aims to analyze serum and plasma samples from patients with late onset Pompe disease treated and not treated with enzyme replacement therapy (ERT) to identify microRNA that could be specific of the disease. The investigators will correlate the concentration of these microRNA with several muscle function tests and quantitative muscle MRI to know whether they are good biomarkers of progression.

NCT ID: NCT02191917 Terminated - Clinical trials for Late-onset Pompe Disease

A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)

Start date: October 21, 2014
Phase:
Study type: Observational

Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .

NCT ID: NCT01924845 Terminated - Clinical trials for Late-onset Pompe Disease

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Start date: April 2014
Phase: Phase 3
Study type: Interventional

Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer. Ambulatory patients who have mild to moderate respiratory impairment will switch directly to receive BMN 701 20 mg/kg by IV infusion every other week. All participants will receive active drug. No dose of existing therapy will be missed - experimental drug is started immediately.